Special Issue "Molecular Imaging in Biopharmaceutical Research and Development"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 1127

Special Issue Editor

Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Korea
Interests: PET pharmacokinetics; molecular imaging research

Special Issue Information

Dear Colleagues,

Biopharmaceuticals, such as immunotherapies, antibody-drug conjugates, and gene and cell therapies, have fundamentally reshaped conventional drug research and development paradigms, which are primarily constructed for small-molecule drugs. However, under the circumstances of techniques and regulations lagging behind advances in biopharmaceuticals, researchers are turning toward novel and innovative techniques to profile the fate and effects of the biopharmaceuticals. Molecular imaging allows for the direct or indirect monitoring and recording of the spatiotemporal distribution of molecular or cellular processes for biochemical, biological or diagnostic therapeutics. Additionally, its application in the development of biopharmaceuticals has gained momentum, ever since investigators found that conventional methods were not suitable for assessing the distribution and changes in biomarkers following the application of the biopharmaceuticals, especially in vivo.

The goal of this Special Issue is to present the latest advances in using molecular imaging for biopharmaceutical research and development, with the ultimate aim of further accelerating biopharmaceutical development by using molecular imaging and personalized therapy.

We welcome reviews and the original research papers regarding novel and innovative molecular imaging methods for profiling and characterizing the distribution and effect of any of the biopharmaceuticals mentioned above. Molecular imaging modalities can also be included, and we also seek state-of-the-art artificial intelligence methods, combined with molecular imaging. Along with biopharmaceuticals, emerging biological entities, such as exosomes, liposomes, and microbiomes are also encouraged for submission.

Dr. Hyun Soo Park
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • molecular imaging
  • drug discovery and development
  • biopharmaceutical
  • cell tracking
  • immunotherapies
  • antibody–drug conjugates
  • pharmacokinetics
  • pharmacodynamics
  • artificial intelligence
  • personalized medicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides
Pharmaceutics 2022, 14(12), 2809; https://doi.org/10.3390/pharmaceutics14122809 - 15 Dec 2022
Viewed by 726
Peptides are small biomolecules known to stimulate or inhibit important functions in the human body. The clinical use of peptides by oral delivery, however, is very limited due to their sensitive structure and physiological barriers present in the gastrointestinal tract. These barriers can [...] Read more.
Peptides are small biomolecules known to stimulate or inhibit important functions in the human body. The clinical use of peptides by oral delivery, however, is very limited due to their sensitive structure and physiological barriers present in the gastrointestinal tract. These barriers can be overcome with chemical and mechanical approaches protease inhibitors, permeation enhancers, and polymeric encapsulation. Studying the success of these approaches pre-clinically with imaging techniques such as fluorescence imaging (IVIS) and optical microscopy is difficult due to the lack of in-depth penetration. In comparison, nuclear imaging provides a better platform to observe the gastrointestinal transit and quantitative distribution of radiolabeled peptides. This review provides a brief background on the oral delivery of peptides and states examples from the literature on how nuclear imaging can help to observe and analyze the gastrointestinal transit of oral peptides. The review connects the fields of peptide delivery and nuclear medicine in an interdisciplinary way to potentially overcome the challenges faced during the study of oral peptide formulations. Full article
(This article belongs to the Special Issue Molecular Imaging in Biopharmaceutical Research and Development)
Show Figures

Figure 1

Back to TopTop